Email this article HIGH INTENSITY STATIN IN ISCHEMIC STROKE: EXPERIENCE FROM A TERTIARY CARE HOSPITAL OF PESHAWAR, PAKISTAN
Abstract
Background: High intensity statins are one of the pillar of secondary stroke prevention. It has been a common practice to prescribe lower-than-recommended statin doses because of concerns regarding drug toxicity in Asians population. This necessitates investigation rather than assumption.
Objective: To determine the short term effect of high intensity statins in secondary prevention of stroke in terms of low density lipoprotein (LDL) reduction and frequency of myopathy.
Methods: A Prospective observational study was conducted in Rehman Medical Institute, Peshawar. patient diagnosed with ischemic stroke, were prescribed high intensity Atrovastatin and rusuvastatin. Baseline modified Rankin Scale along with Creatinine phosphate kinase (CPK), Thyroid stimulating hormone (TSH), Alanine transaminase (ALT) and renal profile were recorded. Patients followed up after 6weeks. On follow up symptoms and signs of myopathy along with serum CPK level were recorded. The patients having myopathy were categorized as per SRM classification.
Results: Of 202 patients, 13 fail to follow up. Among the 189 patients included 59.8% (113) were males whereas (40.2%) 76 were females. The Mean LDL (low density lipoprotein) at admission was 121.43±21.56 mg/dL. Of all, 51.9% of the participants received 40 milligrams of atorvastatin. At 6 weeks follow-up The Mean Low density lipoprotein LDL level were 61.12 ± 27.29. mg/dl. No patient developed symptoms or muscle tenderness on examination. However, 4.2% (8) patients had raised CPK on follow-up and fell into Statin related myopathy (SRM) 0. None of the patients suffered from any other type of SRM.
Conclusions: A very limited percentage of the participants developed mild, asymptomatic myopathy (SRM0). None got any other class of SRM. There was no significant association of myopathy with age, gender, mRs, premorbids and type of statin used. With high intensity statin we managed to achieve desired LDL levels in a significant number of patient on 6 weeks follow up.
Keywords
Full Text:
PDFReferences
Kim AS. Medical Management for Secondary
Stroke Prevention. Continuum (Minneap Minn)
;26(2):435-456. 2. Amarenco P, Lavallée PC, Labreuche J, Albers
GW, Bornstein NM, Canhão P, et al. One-year risk
of stroke after transient ischemic attack or minor
stroke. N Engl J Med 2016;374(16):1533–42. 3. Nanna MG, Navar AM, Zakroysky P, Xiang Q,
Goldberg AC, Robinson J,et al. Association of
patient perceptions of cardiovascular risk and
beliefs on statin drugs with racial differences in
statin use: insights from the patient and provider
assessment of lipid management registry. JAMA
Cardiol 2018;3:739–748. 4. Kleindorfer DO, Cockroft KM, Kernan WN,
Meschia JF, Sharrief AZ. 2021 Guideline for the
Prevention of Strokein Patients With Stroke and
Transient Ischemic Attack Stroke. 2021;52:e364–
e467. 5. Xian Y, Navar AM, Li S, Li Z, Robinson J, Virani
SS,et al. Intensity of Lipid Lowering With Statin
Therapy in Patients With Cerebrovascular Dis-ease Versus Coronary Artery Disease: Insights
from the PALM Registry J Am Heart Assoc 2019
;8(19):e013229. 6. Grover A, Rehan HS, Gupta LK, Yadav M.
Correlation of compliance to statin therapy with
lipid profile and serum HMGCoA reductase
levels in dyslipidemic patients. Indian Heart J.
;69(1):6–10. 7. Virani SS, Woodard LD, Akeroyd JM, Ramsey
DJ, Ballantyne CM, Petersen LA. Is high-inten-sity statin therapy associated with lower statin
adherence compared with low- to moderate-in-tensity statin therapy? Implications of the 2013
American College of Cardiology/American Heart
Association cholesterol management guidelines.
Clin Cardiol. 2014;37(11):653–9. 8. Adams C, Singh K. Geographic variation in the
statin trials: Underrepresentation of Asian pop-ulations. Int J Cardiol. 2020;316:249–251. 9. Wander GS, Jadhav UM, Chemburkar A, Lo-pez M, Gogtay J. Lipids in Health and Disease
;16:130 10. Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster
V, Sperling LS. Utilization of and adherence to
guideline-recommended lipid-lowering therapy
after acute coronary syndrome. J Am Coll Car-diol. 2015;66:184. 11. Naito R, Miyauchi K, Daida H. Racial Differences
in the Cholesterol-Lowering Effect of Statin. J
Atheroscler Thromb, 2017; 24: 19-25. 12. Eastwood SV, Mathur R, Sattar N, Smeeth L,
Bhaskaran K, Chaturvedi N. Ethnic differenc-es in guideline-indicated statin initiation for
people with type 2 diabetes in UK primary
care, 2006–2019: A cohort study. PLoS Med.
;18:e1003672. 13. Po-Sheng Chen, MD, Sheng-Hsiang Lin, PhD,
Cheng-Han Lee, MD, PhD, Hui-Wen Lin, MSc, Yi-Heng Li, MD, PhD Efficacy and Safety of High-in-tensity Statins in Patients with Acute Myocardial
Infarction: An Asian Perspective 14. Fung V, Graetz I, Reed M, Jaffe MG. Patient-re-ported adherence to statin therapy, barriers to
adherence, and perceptions of cardiovascular
risk. PLoS ONE 13(2): e0191817. 15. Flint AC, Conell C, Ren X, Kamel H, Chan SL,
Rao VA et all. Statin adherence is associat-ed with reduced recurrent stroke risk in pa-tients with or without atrial fibrillation. Stroke.
;48(7):1788–94. 16. Zhang J, Zhu P, Liu B, Yao Q, Yan K, Zheng Q et
al. Time to recurrence after first-ever ischaemic
stroke within 3 years and its risk factors in Chi-nese population: A prospective cohort study.
BMJ Open. 2019;9(12). 17. Taguchi I, Iimuro S, Iwata H, Takashima H,
Abe M, Amiya E, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With
Stable Coronary Artery Disease (REAL-CAD):
A Randomized Superiority Trial. Circulation
;137(19):1997-2009. 18. El-Salem K, Ababeneh B, Rudnicki S, Malka-wi A, Alrefai A, Khader Y, Saadeh R, Saydam
M. Prevalence and risk factors of muscle
complications secondary to statins. Muscle
Nerve 2011;44:877–881. 19. Xian Y,Navar AM, Li S, Li Z, Intensity of Lipid
Lowering With Statin Therapy in Patients With
Cerebrovascular Disease Versus Coronary Artery
Disease: Insights from the PALM Registry. J Am
Heart Assoc. 2019;8:e013229. 20. Li YH, Ueng KC, Jeng JS, et al; Writing Group of
Taiwan Lipid Guidelines for High Risk Pa-tients. 2017 Taiwan lipid guidelines for high risk
patients. J Formos Med Assoc 2017;116:217-48. 21. Narasingan SN, Potey AV, Ingole S, Hajare A,
Naik S. Use of statins in India: A survey to un-derstand the prescribing patterns of physicians
in India- SCORE Study”, International Journal
of Current Research 2018;10(03):66330-66334. 22. Gluba-Brzozka A, Franczyk B, Toth PP, Rysz
J, Banach M. Molecular mechanisms of statin
intolerance. Arch Med Sci. 2016;12:645–658. 23. Banach M, Rizzo M, Toth PP, et al. Statin intoler-ance - an attempt at a unified definition. Position
paper from an International Lipid Expert Panel.
Arch Med Sci. 2015;11:1–23. 24. Tobert JA, Newman CB. Statin tolerability: in
defence of placebo controlled trials. Eur J Prev
Cardiol. 2016;23:891–896. 25. Laufs U, Scharnagl H, März W. Statin intolerance.
Curr Opin Lipidol.2015;26:492–501. 26. Keen HI, Krishnarajah J, Bates TR, Watts GF.
Statin myopathy: the fly in the ointment for the
prevention of cardiovascular disease in the 21st
century? Expert Opin Drug Saf. 2014;13:1227–
27. Tariq M, Munir R, Kayani AM. Challenging clin-ical issue of muscle symptoms in statin treated
patients: a comparison with AHA guidelines Pak
Heart J 2017; 50 (03): 169-74. 28. Riaz R, Merchant AZ, Ul Haq MS, Nasir SAR,
Rizvi Y, Khan JA, et al. Statins Everyday Versus
Alternate days: Is There a Difference in Myalgia
rates? Indian Heart J 2018; 70: 492-6. 29. Li DQ, Kim RB, McArthur E, Fleet JL, Hegele
RA, Shah BR, et al.Statin Safety in Chinese: A
Population-Based Study of Older Adults. PLoS
ONE. 2016;11(3): e0150990. 30. Ward NC, Watts GF, Eckel RH. Statin Toxicity.
Mechanistic Insights and Clinical Implications. 31. Tramacere I, Boncoraglio GB, Banzi R, Del
Giovane C, Kwag KH, Squizzato A, et al. Com-parison of statins for secondary prevention in
patients with ischemic stroke or transient isch-emic attack: a systematic review and network
meta-analysis. BMC Med. 2019 Mar 26;17(1):67. 32. Tsankof A, Tziomalos K. The Role of Lipid-Low-ering Treatment in the Secondary Prevention of
Ischemic Stroke. Diseases. 2021;10(1):3
Refbacks
- There are currently no refbacks.
Copyright (c) 2025 Wajeeha Qayyum, Muhammad Shahid Iqbal, sohail Khan, Zaland Ahmed Yousafzai, Muhammad Fozan Khan, Rizwan Amin Kundi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Gomal Medical College, Daraban Road, Dera Ismail Khan, Pakistan
ISSN: 1819-7973, e-ISSN: 1997-2067
Website: https://www.gmcdikhan.edu.pk
Phone: +92-966-747373
